Show Notes
Bruton tyrosine kinase (BTK) inhibitors are used to treat cancers caused by defective B cells, such as chronic lymphocytic leukaemia, B-cell lymphomas and Waldenström macroglobulinemia (WM). While B-cell malignancies are relatively rare cancers, their incidence is increasing. There are significant side effects and drug interactions associated with these therapies, and as the clinical use of BTK inhibitors increases, so does the need for pharmacists and pharmacy teams to be aware of them.
In this episode of The PJ Pod, Caitlin Killen, assistant clinical editor, speaks to a patient who has received these therapies, as well as with two experts to find out more about the different BTK inhibitor classes, their mechanisms of action and considerations for their use in practice, with a focus on WM.
More from The PJ Pod
For Tase Oputu, becoming the first president of the Royal College of Pharmacy is “the greatest honour of my career”, and she says the move to a royal college is already changing how pharmacy is received by policymakers.
In this episode of Pharmacy Inside Jobs, senior editor, research and learning Alex Clabburn talks to Ed Hindle.
Electronic Prescription System (EPS) nominations connect patients with the pharmacy where they can collect their medication – and often access other services, help and advice while they’re there.
In this episode of Pharmacy Inside Jobs, Joanna Robertson, senior clinical reporter, talks to Mark Stuart, a sports pharmacist whose 25-year career has spanned Olympic, Paralympic and Commonwealth games, as well as anti-doping education at the International Testing Agency.
In this episode of The PJ Pod, senior features editor Siobhan Chan examines how the issue of antimicrobial resistance (AMR) is being communicated outside of traditional clinical and policy settings.